Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM, Lasho TL.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):450-459. doi: 10.1182/hematology.2020000130.
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM, Lasho T.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):460-464. doi: 10.1182/hematology.2020000163.
Regarding the predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable.
Chen S, Zhou C.
Am J Clin Pathol. 2024 Nov 4;162(5):537. doi: 10.1093/ajcp/aqae141.
Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM, Zeidan AM.
Best Pract Res Clin Haematol. 2020 Jun;33(2):101132. doi: 10.1016/j.beha.2019.101132. Epub 2019 Dec 6.
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.
Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S.
Blood. 2018 Nov 8;132(19):2100-2103. doi: 10.1182/blood-2018-05-848473. Epub 2018 Sep 21.
Reply to "Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: a Bone Marrow Pathology Group study".
Crane GM, Xie Y, Rogers HJ.
Am J Clin Pathol. 2024 Nov 4;162(5):538-539. doi: 10.1093/ajcp/aqae142.
How I manage myeloproliferative neoplasm-unclassifiable: Practical approaches for 2022 and beyond.
McLornan DP, Hargreaves R, Hernández-Boluda JC, Harrison CN.
Br J Haematol. 2022 May;197(4):407-416. doi: 10.1111/bjh.18087. Epub 2022 Feb 22.
Myelodysplastic/myeloproliferative neoplasms.
Cazzola M, Malcovati L, Invernizzi R.
Hematology Am Soc Hematol Educ Program. 2011;2011:264-72. doi: 10.1182/asheducation-2011.1.264.
Myelodysplastic/myeloproliferative neoplasms.
Hyjek E, Vardiman JW.
Semin Diagn Pathol. 2011 Nov;28(4):283-97. doi: 10.1053/j.semdp.2011.07.002.
Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the 'unclassifiable'.
Oganesyan A, Madero-Marroquin R, Patel AA.
Curr Opin Hematol. 2026 Mar 1;33(2):45-50. doi: 10.1097/MOH.0000000000000907. Epub 2025 Dec 29.
